IMAB Stock Overview
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
I-Mab Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.81 |
52 Week High | US$3.45 |
52 Week Low | US$1.16 |
Beta | 1.11 |
1 Month Change | -1.63% |
3 Month Change | 0.56% |
1 Year Change | -40.26% |
3 Year Change | -96.98% |
5 Year Change | n/a |
Change since IPO | -85.52% |
Recent News & Updates
Recent updates
I-Mab: Trading Below Net Cash With Multiple Upside Options
Feb 18We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate
Feb 08I-Mab: Another CD47 Inhibitor Biotech With Great Potential
Sep 27I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome
Sep 13I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M
Aug 30I-Mab and senior executives may buy $40M worth of shares; stock up 10%
Aug 23Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts
Aug 20I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China
Jul 22I-Mab Valuation Offers A Biotech Investment Opportunity
Jun 23Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth
May 24I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat
May 06Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates
Apr 01I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase
Jan 03I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment
Oct 14Drug Maker I-Mab Wins Plaudits As Analysts Urge Caution On Soaring Stock
Jul 02I-Mab adds gastrointestinal oncology expert Andrew Zhu to Scientific Advisory Board
Jun 21I-Mab in talks seeking a billion-dollar deal for cancer therapy: Bloomberg
Jun 14Shareholder Returns
IMAB | US Biotechs | US Market | |
---|---|---|---|
7D | 0.6% | 0.4% | 1.0% |
1Y | -40.3% | 0.9% | 21.9% |
Return vs Industry: IMAB underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: IMAB underperformed the US Market which returned 24.9% over the past year.
Price Volatility
IMAB volatility | |
---|---|
IMAB Average Weekly Movement | 9.2% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMAB has not had significant price volatility in the past 3 months.
Volatility Over Time: IMAB's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Raj Kannan | www.i-mabbiopharma.com |
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers.
I-Mab Fundamentals Summary
IMAB fundamental statistics | |
---|---|
Market cap | US$146.07m |
Earnings (TTM) | -US$202.46m |
Revenue (TTM) | US$3.82m |
38.3x
P/S Ratio-0.7x
P/E RatioIs IMAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMAB income statement (TTM) | |
---|---|
Revenue | CN¥27.64m |
Cost of Revenue | CN¥0 |
Gross Profit | CN¥27.64m |
Other Expenses | CN¥1.49b |
Earnings | -CN¥1.47b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -18.16 |
Gross Margin | 100.00% |
Net Profit Margin | -5,302.03% |
Debt/Equity Ratio | 1.7% |
How did IMAB perform over the long term?
See historical performance and comparison